<?xml version="1.0" encoding="UTF-8"?>
<rss xmlns:atom="http://www.w3.org/2005/Atom" version="2.0"><channel><atom:link href="https://www.dovepress.com/feed/journal/111" rel="self" type="application/rss+xml"/><title>Vaccine: Development and Therapy</title><link>https://www.dovepress.com/feed/journal/111</link><description>New articles released by Dove Press for Vaccine: Development and Therapy</description><language>en-us</language><copyright>2026, Dove Press</copyright><webMaster>angela@dovepress.com (Angela Jones)</webMaster><generator>Dove Press Vaccine: Development and Therapy</generator><image><title>Vaccine: Development and Therapy</title><link>https://www.dovepress.com/feed/journal/111</link><url>https://www.dovepress.com/assets/img/addon/rss-banner.jpg</url><width>140</width><height>140</height></image><item><title>The new first-line defense: the potential of nasopharyngeal colonization in vaccine strategies</title><link>https://www.dovepress.com/the-new-first-line-defense-the-potential-of-nasopharyngeal-colonizatio-peer-reviewed-fulltext-article-VDT</link><category>Vaccine: Development and Therapy</category><pubDate>Mon, 17 Oct 2016 14:34:00 +1300</pubDate><guid isPermaLink="true">https://doi.org/10.2147/VDT.S89026</guid></item><item><title>Management of visceral leishmaniasis with therapeutic vaccines</title><link>https://www.dovepress.com/management-of-visceral-leishmaniasis-with-therapeutic-vaccines-peer-reviewed-fulltext-article-VDT</link><category>Vaccine: Development and Therapy</category><pubDate>Wed, 28 Sep 2016 13:52:00 +1300</pubDate><guid isPermaLink="true">https://doi.org/10.2147/VDT.S110654</guid></item><item><title>RTS,S malaria vaccine development: progress and considerations for postapproval introduction</title><link>https://www.dovepress.com/rtss-malaria-vaccine-development-progress-and-considerations-for-posta-peer-reviewed-fulltext-article-VDT</link><category>Vaccine: Development and Therapy</category><pubDate>Mon, 20 Jun 2016 14:43:00 +1200</pubDate><guid isPermaLink="true">https://doi.org/10.2147/VDT.S53028</guid></item><item><title>Tularemia vaccine development: paralysis or progress?</title><link>https://www.dovepress.com/tularemia-vaccine-development-paralysis-or-progress-peer-reviewed-fulltext-article-VDT</link><category>Vaccine: Development and Therapy</category><pubDate>Wed, 04 May 2016 11:08:00 +1200</pubDate><guid isPermaLink="true">https://doi.org/10.2147/VDT.S85545</guid></item><item><title>Pertussis vaccine in pregnant women: safety and uptake</title><link>https://www.dovepress.com/pertussis-vaccine-in-pregnant-women-safety-and-uptake-peer-reviewed-fulltext-article-VDT</link><category>Vaccine: Development and Therapy</category><pubDate>Wed, 09 Mar 2016 11:31:00 +1300</pubDate><guid isPermaLink="true">https://doi.org/10.2147/VDT.S56413</guid></item><item><title>Hendra and Nipah viruses: pathogenesis, animal models and recent breakthroughs in vaccination</title><link>https://www.dovepress.com/hendra-and-nipah-viruses-pathogenesis-animal-models-and-recent-breakth-peer-reviewed-fulltext-article-VDT</link><category>Vaccine: Development and Therapy</category><pubDate>Mon, 28 Sep 2015 17:01:00 +1300</pubDate><guid isPermaLink="true">https://doi.org/10.2147/VDT.S86482</guid></item><item><title>Development of a vaccine for Chlamydia trachomatis: challenges and current progress</title><link>https://www.dovepress.com/development-of-a-vaccine-for-chlamydia-trachomatis-challenges-and-curr-peer-reviewed-fulltext-article-VDT</link><category>Vaccine: Development and Therapy</category><pubDate>Mon, 17 Aug 2015 14:51:00 +1200</pubDate><guid isPermaLink="true">https://doi.org/10.2147/VDT.S69487</guid></item><item><title>Current and future prophylactic vaccines for hepatitis C virus</title><link>https://www.dovepress.com/current-and-future-prophylactic-vaccines-for-hepatitis-c-virus-peer-reviewed-fulltext-article-VDT</link><category>Vaccine: Development and Therapy</category><pubDate>Tue, 11 Aug 2015 17:01:00 +1200</pubDate><guid isPermaLink="true">https://doi.org/10.2147/VDT.S48437</guid></item><item><title>Immunosenescence: implications for vaccination programs in the elderly</title><link>https://www.dovepress.com/immunosenescence-implications-for-vaccination-programs-in-the-elderly-peer-reviewed-fulltext-article-VDT</link><category>Vaccine: Development and Therapy</category><pubDate>Thu, 06 Aug 2015 14:30:00 +1200</pubDate><guid isPermaLink="true">https://doi.org/10.2147/VDT.S63888</guid></item><item><title>A database in ACCESS for assessing vaccine serious adverse events</title><link>https://www.dovepress.com/a-database-in-access-for-assessing-vaccine-serious-adverse-events-peer-reviewed-fulltext-article-VDT</link><category>Vaccine: Development and Therapy</category><pubDate>Mon, 20 Apr 2015 15:08:00 +1200</pubDate><guid isPermaLink="true">https://doi.org/10.2147/VDT.S82427</guid></item><item><title>Evaluating the safety and immunogenicity of yellow fever vaccines: a systematic review</title><link>https://www.dovepress.com/evaluating-the-safety-and-immunogenicity-of-yellow-fever-vaccines-a-sy-peer-reviewed-fulltext-article-VDT</link><category>Vaccine: Development and Therapy</category><pubDate>Mon, 20 Apr 2015 15:05:00 +1200</pubDate><guid isPermaLink="true">https://doi.org/10.2147/VDT.S56779</guid></item><item><title>Vaccines for metabolic diseases: current perspectives</title><link>https://www.dovepress.com/vaccines-for-metabolic-diseases-current-perspectives-peer-reviewed-fulltext-article-VDT</link><category>Vaccine: Development and Therapy</category><pubDate>Tue, 02 Sep 2014 16:00:00 +1200</pubDate><guid isPermaLink="true">https://doi.org/10.2147/VDT.S47623</guid></item><item><title>Challenges to developing effective streptococcal vaccines to prevent rheumatic fever and rheumatic heart disease</title><link>https://www.dovepress.com/challenges-to-developing-effective-streptococcal-vaccines-to-prevent-r-peer-reviewed-fulltext-article-VDT</link><category>Vaccine: Development and Therapy</category><pubDate>Fri, 02 May 2014 00:00:00 +1200</pubDate><guid isPermaLink="true">https://doi.org/10.2147/VDT.S45037</guid></item><item><title>Current progress toward vaccines against Toxoplasma gondii</title><link>https://www.dovepress.com/current-progress-toward-vaccines-against-toxoplasma-gondii-peer-reviewed-fulltext-article-VDT</link><category>Vaccine: Development and Therapy</category><pubDate>Wed, 16 Apr 2014 00:00:00 +1200</pubDate><guid isPermaLink="true">https://doi.org/10.2147/VDT.S57474</guid></item><item><title>Immunization and chemical conjugation of Bm95 obtained from Pichia pastoris enhances the immune response against vaccinal protein and Neisseria meningitidis capsular polysaccharide</title><link>https://www.dovepress.com/immunization-and-chemical-conjugation-of-bm95-obtained-from-pichia-pas-peer-reviewed-fulltext-article-VDT</link><category>Vaccine: Development and Therapy</category><pubDate>Fri, 07 Mar 2014 00:00:00 +1300</pubDate><guid isPermaLink="true">https://doi.org/10.2147/VDT.S57043</guid></item><item><title>Changing epidemiology of hepatitis A virus in Indian children</title><link>https://www.dovepress.com/changing-epidemiology-of-hepatitis-a-virus-in-indian-children-peer-reviewed-fulltext-article-VDT</link><category>Vaccine: Development and Therapy</category><pubDate>Sat, 18 Jan 2014 00:00:00 +1300</pubDate><guid isPermaLink="true">https://doi.org/10.2147/VDT.S53324</guid></item><item><title>Immunogenicity and safety of live attenuated hepatitis A vaccine (Biovac-A™) in healthy Indian children</title><link>https://www.dovepress.com/immunogenicity-and-safety-of-live-attenuated-hepatitis-a-vaccine-biova-peer-reviewed-fulltext-article-VDT</link><category>Vaccine: Development and Therapy</category><pubDate>Thu, 19 Dec 2013 00:00:00 +1300</pubDate><guid isPermaLink="true">https://doi.org/10.2147/VDT.S52736</guid></item><item><title>Melanoma vaccines: trials and tribulations</title><link>https://www.dovepress.com/melanoma-vaccines-trials-and-tribulations-peer-reviewed-fulltext-article-VDT</link><category>Vaccine: Development and Therapy</category><pubDate>Thu, 10 Oct 2013 00:00:00 +1300</pubDate><guid isPermaLink="true">https://doi.org/10.2147/VDT.S32396</guid></item><item><title>Review of recent literature on microneedle vaccine delivery technologies</title><link>https://www.dovepress.com/review-of-recent-literature-on-microneedle-vaccine-delivery-technologi-peer-reviewed-fulltext-article-VDT</link><category>Vaccine: Development and Therapy</category><pubDate>Thu, 22 Aug 2013 00:00:00 +1200</pubDate><guid isPermaLink="true">https://doi.org/10.2147/VDT.S34682</guid></item><item><title>Current research and clinical trials for a vaccine against Chikungunya virus</title><link>https://www.dovepress.com/current-research-and-clinical-trials-for-a-vaccine-against-chikungunya-peer-reviewed-fulltext-article-VDT</link><category>Vaccine: Development and Therapy</category><pubDate>Fri, 09 Aug 2013 00:00:00 +1200</pubDate><guid isPermaLink="true">https://doi.org/10.2147/VDT.S25513</guid></item><item><title>Forced degradation studies: an essential tool for the formulation development of vaccines</title><link>https://www.dovepress.com/forced-degradation-studies-an-essential-tool-for-the-formulation-devel-peer-reviewed-fulltext-article-VDT</link><category>Vaccine: Development and Therapy</category><pubDate>Thu, 13 Jun 2013 00:00:00 +1200</pubDate><guid isPermaLink="true">https://doi.org/10.2147/VDT.S41998</guid></item><item><title>Key feasibility considerations when conducting vaccine clinical trials in Asia–Pacific countries</title><link>https://www.dovepress.com/key-feasibility-considerations-when-conducting-vaccine-clinical-trials-peer-reviewed-fulltext-article-VDT</link><category>Vaccine: Development and Therapy</category><pubDate>Tue, 19 Mar 2013 00:00:00 +1300</pubDate><guid isPermaLink="true">https://doi.org/10.2147/VDT.S41903</guid></item><item><title>Cytolethal distending toxin as virulence factor, protective antigen, and target for vaccine development</title><link>https://www.dovepress.com/cytolethal-distending-toxin-as-virulence-factor-protective-antigen-and-peer-reviewed-fulltext-article-VDT</link><category>Vaccine: Development and Therapy</category><pubDate>Thu, 06 Dec 2012 00:00:00 +1300</pubDate><guid isPermaLink="true">https://doi.org/10.2147/VDT.S32401</guid></item><item><title>Assessment of chicken protection against Campylobacter jejuni infection by immunization with avirulent Salmonella enterica sv. Typhimurium strain producing Campylobacter CjaD/Pal protein</title><link>https://www.dovepress.com/assessment-of-chicken-protection-against-campylobacter-jejuni-infectio-peer-reviewed-fulltext-article-VDT</link><category>Vaccine: Development and Therapy</category><pubDate>Fri, 31 Aug 2012 00:00:00 +1200</pubDate><guid isPermaLink="true">https://doi.org/10.2147/VDT.S33742</guid></item><item><title>Realizing the promise of breast cancer vaccines</title><link>https://www.dovepress.com/realizing-the-promise-of-breast-cancer-vaccines-peer-reviewed-fulltext-article-VDT</link><category>Vaccine: Development and Therapy</category><pubDate>Wed, 22 Aug 2012 00:00:00 +1200</pubDate><guid isPermaLink="true">https://doi.org/10.2147/VDT.S25532</guid></item><item><title>Reasons for not having received influenza vaccination and its predictors in Canadians</title><link>https://www.dovepress.com/reasons-for-not-having-received-influenza-vaccination-and-its-predicto-peer-reviewed-fulltext-article-VDT</link><category>Vaccine: Development and Therapy</category><pubDate>Mon, 13 Aug 2012 00:00:00 +1200</pubDate><guid isPermaLink="true">https://doi.org/10.2147/VDT.S32618</guid></item><item><title>New recombinant vaccines for the prevention of meningococcal B disease</title><link>https://www.dovepress.com/new-recombinant-vaccines-for-the-prevention-of-meningococcal-b-disease-peer-reviewed-fulltext-article-VDT</link><category>Vaccine: Development and Therapy</category><pubDate>Wed, 27 Jun 2012 00:00:00 +1200</pubDate><guid isPermaLink="true">https://doi.org/10.2147/VDT.S25458</guid></item><item><title>Advances in the development of vaccines for dengue fever</title><link>https://www.dovepress.com/advances-in-the-development-of-vaccines-for-dengue-fever-peer-reviewed-fulltext-article-VDT</link><category>Vaccine: Development and Therapy</category><pubDate>Fri, 04 May 2012 00:00:00 +1200</pubDate><guid isPermaLink="true">https://doi.org/10.2147/VDT.S22577</guid></item><item><title>Recombinant Rhipicephalus appendiculatus gut (Ra86) and salivary gland cement (Trp64) proteins as candidate antigens for inclusion in tick vaccines: protective effects of Ra86 on infestation with adult R. appendiculatus</title><link>https://www.dovepress.com/recombinant-rhipicephalus-appendiculatus-gut-ra86-and-salivary-gland-c-peer-reviewed-fulltext-article-VDT</link><category>Vaccine: Development and Therapy</category><pubDate>Wed, 23 Nov 2011 00:00:00 +1300</pubDate><guid isPermaLink="true">https://doi.org/10.2147/VDT.S20827</guid></item><item><title>The utility of human challenge studies in vaccine development: lessons learned from cholera</title><link>https://www.dovepress.com/the-utility-of-human-challenge-studies-in-vaccine-development-lessons--peer-reviewed-fulltext-article-VDT</link><category>Vaccine: Development and Therapy</category><pubDate>Wed, 05 Oct 2011 00:00:00 +1300</pubDate><guid isPermaLink="true">https://doi.org/10.2147/VDT.S23634</guid></item></channel></rss>
